Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

We describe the first-in-human dose-escalation trial for ALRN-6924, a stabilized, cell-permeating peptide that disrupts p53 inhibition by mouse double minute 2 (MDM2) and MDMX to induce cell-cycle arrest or apoptosis in TP53-wild-type (WT) tumors. Two schedules were evaluated for safety, pharmacokin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2021-10, Vol.27 (19), p.5236-5247
Hauptverfasser:	Saleh, Mansoor N, Patel, Manish R, Bauer, Todd M, Goel, Sanjay, Falchook, Gerald S, Shapiro, Geoffrey I, Chung, Ki Y, Infante, Jeffrey R, Conry, Robert M, Rabinowits, Guilherme, Hong, David S, Wang, Judy S, Steidl, Ulrich, Naik, Gurudatta, Guerlavais, Vincent, Vukovic, Vojislav, Annis, D Allen, Aivado, Manuel, Meric-Bernstam, Funda
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - adverse effects Clinical Trials: Targeted Therapy Dose-Response Relationship, Drug Fatigue Humans Lymphoma - drug therapy Lymphoma - genetics Maximum Tolerated Dose Mice Neoplasms - drug therapy Neoplasms - genetics Proto-Oncogene Proteins c-mdm2 - metabolism Tumor Suppressor Protein p53 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!